Xencor has reported a loss for the first quarter and failed to meet revenue estimates. The company's performance may be impacted by factors affecting the biopharma sector, which is showing signs of recovery. The situation is being watched in the context of the broader industry, with other companies such as Akebia Therapeutics also being monitored.